|
|
| SADARANGANI,ANIL; SALGADO,ANA MARÍA; KATO,SUMIE; PINTO,MAURICIO; CARVAJAL,ANDRÉS; MONSO,CAROLINA; OWEN,GARETH I; VIGIL,PILAR. |
| Estrogen and progestin combination in hormone replacement therapy (HRT) increases the incidence of breast cancer, but decreases the endometrial cancer risk of unopposed estrogen. Therefore, a SERM such as Tibolone, that delivers the beneficial, but not the adverse side effects, of steroid hormones would be clinically advantageous. However, data from the Million Women Study suggests that Tibolone increases the risk of both breast and endometrial cancer. Herein, we assessed the estrogenic and progestagenic actions of Tibolone using transvaginal sonography studies and an in vitro model of breast (ZR-75, MCF7) and endometrial cancer (Ishikawa). The known cancer associated proteins (ER, EGFR, STAT5, tissue factor and Bcl-xL) were selected for study.... |
| Tipo: Journal article |
Palavras-chave: Breast/endometrium cancer estrogenic HRT progestagenic & Tibolone. |
| Ano: 2005 |
URL: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602005000200014 |
| |
